调节1型糖尿病β细胞自身免疫的挑战
本文回顾了数十项旨在预防或逆转1型糖尿病的免疫治疗临床试验未能取得实用成果的原因,包括未充分认识疾病异质性、不当使用啮齿动物模型、未充分处理免疫与代谢因素、试验设计欠佳及对发病机制理解不足。文章指出,疾病分期相关努力和临床试验的机制数据带来谨慎乐观,提示基于免疫的方法有望进入临床实践。
要点
- 数十项免疫治疗试验未能在实用层面实现预防或逆转1型糖尿病。
- 失败原因包括疾病异质性认识不足、啮齿动物模型使用不当和试验设计欠佳。
- 疾病分期与临床试验机制数据带来谨慎乐观,免疫干预有望进入临床。
核心结论
- 尽管数十项免疫治疗临床试验未能在实用层面实现预防或逆转1型糖尿病,但近期知识进展与疾病分期及机制数据带来谨慎乐观。
研究设计与样本
- 本文为系列综述,回顾了数十项旨在预防和逆转1型糖尿病的免疫治疗临床试验。
主要发现
- 数十项临床试验未能以实用形式实现预防或逆转1型糖尿病的目标。
- 失败原因包括未认识疾病异质性、不当使用啮齿动物模型、未充分处理免疫与代谢因素、试验设计欠佳及对发病机制理解不足。
临床怎么用
- 疾病分期相关努力和临床试验的机制数据提示,基于免疫的方法预防1型糖尿病β细胞丢失有望进入临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the conceptual advance about four decades ago that type 1 diabetes represents an autoimmune disease, hope arose that immune-based therapies would soon emerge to prevent and reverse the disorder. However, despite dozens of clinical trials seeking to achieve these goals, the promise remains unfulfilled, at least in a pragmatic form. With the benefit of hindsight, several important reasons are likely to account for this disappointing outcome, including failure to appreciate disease heterogeneity, inappropriate use of rodent models of disease, inadequacies in addressing the immunological and metabolic contributions to the disease, suboptimal trial designs, and lack of a clear understanding of the pathogenesis of type 1 diabetes. In this Series paper, we convey how recent knowledge gains in these areas, combined with efforts related to disease staging and emerging mechanistic data from clinical trials, provide cautious optimism that immune-based approaches to prevent the loss of β cells in type 1 diabetes will emerge into clinical practice.
引用
- Atkinson MA, Roep BO, Posgai A, et al. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2018. PMID: 30528099. doi:10.1016/S2213-8587(18)30112-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。